Drug Discovery Award supports academic scientists with research resources and biopharma expertise to advance promising cancer targets toward new therapeutic agents and preclinical development.
Funder: The Mark Foundation for Cancer Research
Due Dates (Anticipated): Not yet announced
Funding Amounts: Research resources and biopharma R&D expertise (post-target validation through early lead development)
Summary: Supports academic drug discovery efforts that advance promising cancer targets toward new therapeutic agents and preclinical development.
The Mark Foundation for Cancer Research’s Drug Discovery Award helps turn promising academic discoveries into new cancer therapies and platforms that can substantially improve patient outcomes. The program addresses the limited resources and drug discovery know-how available to academic scientists working on promising new cancer targets.
Support spans post-target validation through early lead development, with the goal of progressing new therapeutic agents toward preclinical development. Alongside research resources, investigators receive advice from seasoned biopharma research and development scientists. These experts guide activities on the critical path to developing a new therapeutic agent, helping bridge the gap between academic discovery and therapeutic development.